FEN1-IN-4
10mM in DMSO
- Product Code: 186831
CAS:
1995893-58-7
| Molecular Weight: | 232.24 g./mol | Molecular Formula: | C₁₂H₁₂N₂O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
FEN1-IN-4 is a potent and selective inhibitor of flap endonuclease 1 (FEN1), an enzyme involved in DNA replication and repair processes. Its primary application lies in cancer research, where it is used to target cancer cells with defective DNA repair pathways, particularly those exhibiting synthetic lethality with homologous recombination deficiencies such as in BRCA-mutated tumors. By inhibiting FEN1, FEN1-IN-4 disrupts base excision repair and Okazaki fragment maturation, leading to accumulation of DNA damage and cell death in rapidly dividing tumor cells. It serves as a valuable tool compound in studies exploring DNA repair inhibition as a therapeutic strategy, especially in combination with other DNA-damaging agents like chemotherapy or PARP inhibitors. Its use is currently limited to preclinical research, aiding in the validation of FEN1 as an oncology drug target.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | $314.71 |
+
-
|
FEN1-IN-4
FEN1-IN-4 is a potent and selective inhibitor of flap endonuclease 1 (FEN1), an enzyme involved in DNA replication and repair processes. Its primary application lies in cancer research, where it is used to target cancer cells with defective DNA repair pathways, particularly those exhibiting synthetic lethality with homologous recombination deficiencies such as in BRCA-mutated tumors. By inhibiting FEN1, FEN1-IN-4 disrupts base excision repair and Okazaki fragment maturation, leading to accumulation of DNA damage and cell death in rapidly dividing tumor cells. It serves as a valuable tool compound in studies exploring DNA repair inhibition as a therapeutic strategy, especially in combination with other DNA-damaging agents like chemotherapy or PARP inhibitors. Its use is currently limited to preclinical research, aiding in the validation of FEN1 as an oncology drug target.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :